Evidence map›Paper›PMID 36069950›Full record

Trial reportPsychopharmacology2022

Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial.

Archana Mishra, K H Reeta, Sudhir Chandra Sarangi, Rituparna Maiti, Mamta Sood

Erratum issuedOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Nutraceuticals in Psychiatric Disorders: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Variations to plasma HSchizophrenia (Heidelberg, Germany) · 2024
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Archana MishraDepartment of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.ORCID http://orcid.org/0000-0001-8837-299X
K H ReetaDepartment of Pharmacology, All India Institute of Medical Sciences, New Delhi, India. reetakh@gmail.com.ORCID http://orcid.org/0000-0002-3824-5498
Sudhir Chandra SarangiDepartment of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.ORCID http://orcid.org/0000-0002-3587-0968
Rituparna MaitiDepartment of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, India.ORCID http://orcid.org/0000-0003-4063-9178
Mamta SoodDepartment of Psychiatry, All India Institute of Medical Sciences, New Delhi, India.
All India Institute of Medical Sciences · INAll India Institute of Medical Sciences Bhubaneswar · IN

Funding

Indian Council of Medical Research (IN) 3/2/Dec-2019/PG-Thesis-HRD (12)
6 · The paper itself

Abstract

rationaleAlpha lipoic acid is known to reverse NMDA receptor hypofunction in addition to dopamine receptor blockade activity. It also enhances neurotrophic factors and has antioxidant potential. These properties combined together may be beneficial for treatment-resistant schizophrenia (TRS).

objectivesThis study evaluates the effect of alpha lipoic acid (ALA) on psychopathological scores (positive, negative, cognitive), neurotrophic factors and oxidative stress in TRS.

methodsA pilot randomized double-blind placebo-controlled parallel design trial was conducted in 20 patients with TRS. After initial screening, participants were randomized into test (add-on ALA) and control (add-on placebo) groups. After recruitment, clinical evaluations with scale for assessment of positive symptoms and negative symptoms (SAPS and SANS), schizophrenia cognitive rating scale (SCoRS), UKU side effect rating scale were done. Serum levels of BDNF, MDA, and GSH were estimated. Patients were followed up for 8 weeks, and clinical and biochemical evaluations were repeated. Adherence to medication was evaluated at follow-up.

resultsA significantly greater improvement was found in SANS score in the test group when compared to control (Mann-Whitney U = 17.0; p = 0.021), whereas there was no significant improvement in SAPS score (Mann-Whitney U = 41.5; p = 0.780). A significant increase in BDNF levels was observed in the control group when compared to ALA (U = 20.0; p = 0.041). No significant differences were found between the test and control groups in serum MDA (U = 30.0; p = 0.221), serum GSH (U = 40.0; p = 0.683), and medication adherence rating scale (MARS) scores (U = 44.0; p = 0.934).

conclusionsALA supplementation improved psychopathology and decreased oxidative stress in patients with TRS. This study thus shows the potential of adjunctive ALA in TRS.

trial registrationThe study was prospectively registered in Clinical Trial Registry of India (CTRI/2020/03/023707 dated 02.03.2020).

Indexed as

Antipsychotic AgentsSchizophreniaThioctic AcidAntioxidantsBrain-Derived Neurotrophic FactorDouble-Blind MethodDrug Therapy, CombinationHumansPilot ProjectsPsychiatric Status Rating ScalesReceptors, DopamineReceptors, N-Methyl-D-AspartateSchizophrenia, Treatment-ResistantTreatment OutcomeAntioxidantsAntipsychotic AgentsBrain-Derived Neurotrophic FactorReceptors, DopamineReceptors, N-Methyl-D-AspartateThioctic AcidAlpha lipoic acidOxidative stress markersPsychopathologySchizophrenia, Treatment-resistant

Identifiers

PMID36069950
PMCPMC9449282
OpenAlexW4294917579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.